RxDoctor Payments DataLook up a doctor →

Robert Smythe, MD

Internal Medicine · Yuma, AZNPI 1306874607

Payments from drug & device makers

$1,076,261in general payments, 2019–2025

Across 403 payments — averaging $2670.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$499K
  • Eli Lilly$448K
  • Genentech, Inc.$38K
  • Taro Pharmaceuticals USA, Inc.$25K
  • Boehringer Ingelheim International GmbH$18K
  • Sanofi US Services Inc.$18K
  • plus $30K from 40 others
$440in research payments, 2019–2025

Across 1 payment — averaging $440.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$440

What the payments were for

  • Food & beverage$4,604100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,076,261 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$1,067,462
Medicare patients
1,922
Services billed
45,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$58,113
OzempicSemaglutide25$44,982
JardianceEmpagliflozin29$37,381
MounjaroTirzepatide14$14,632
Rosuvastatin Calcium176$2,926
Losartan Potassium155$1,815
Celecoxib12$1,762
Naproxen35$1,595
Tamsulosin Hcl57$1,576
ProgesteroneProgesterone, Micronized18$1,285
Dutasteride21$1,121
Amlodipine Besylate134$1,042
Levothyroxine Sodium100$1,042
Atorvastatin Calcium87$1,031
Lisinopril110$938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$206$58,11343 claims
Novo NordiskOzempic$289$44,98225 claims
Boehringer IngelheimJardiance$498,667$37,38129 claims
Lilly USA, LLCMounjaro$293$14,63214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Yuma

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →